Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus opthalmic - Marinomed Biotechnologie

Next Previous
Drug Profile

Tacrolimus opthalmic - Marinomed Biotechnologie

Alternative Names: MAM-1003-1; Tacrosolv - Marinomed Biotechnologie

Latest Information Update: 08 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marinomed Biotechnologie
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Ocular herpes simplex

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis; Ocular herpes simplex

Most Recent Events

  • 08 Oct 2025 Marinomed Biotechnologie has patent protection for Tacrosolv in (Marinomed Biotechnologie pipeline; October 2025)
  • 23 Sep 2025 Tacrolimus opthalmic - Marinomed Biotechnologie is available for licensing as of 23 Sep 2025. https://www.marinomed.com/en/
  • 04 Aug 2020 Phase-II clinical trials in Allergic rhinoconjunctivitis in Austria (Ophthalmic) (NCT04532710)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top